```html

Quasi‑Severe Asthma – Comprehensive Medical Guide

Overview

Quasi‑severe asthma is a term used by pulmonologists to describe a phenotype that falls between moderate‑persistent and severe asthma. Patients experience frequent symptoms and exacerbations that require step‑up therapy, yet they do not meet the full criteria for “severe asthma” as defined by the Global Initiative for Asthma (GINA). The “quasi‑” prefix reflects that the disease behaves like severe asthma in many respects—high medication burden, reduced quality of life, and increased health‑care utilization—while still responding to aggressive controller therapy.

Who it affects: The condition is most common in adults aged 18‑55, but adolescents can also develop quasi‑severe disease, especially if they have a history of poorly controlled moderate asthma. Women are slightly more affected (≈55 % of cases) consistent with the overall gender distribution of asthma.

Prevalence: Precise global estimates are limited because the classification is relatively new, but epidemiologic studies in high‑income countries suggest that about 5‑10 % of the asthma population may have quasi‑severe disease. In the United States, where roughly 25 million people have asthma (CDC, 2023), that translates to an estimated 1.2‑2.5 million individuals.

Symptoms

Symptoms of quasi‑severe asthma are similar to those of other asthma phenotypes but are more frequent, intense, or refractory to low‑dose inhaled therapy.

Core respiratory symptoms

• Wheezing: High‑pitched whistling sound, especially during exhalation.
• Dyspnea (shortness of breath): May occur at rest or with minimal activity.
• Chest tightness: A feeling of pressure or “band” around the chest.
• Cough: Often worse at night or early morning, can be dry or produce minimal sputum.

Frequency & severity markers

• Symptoms on > 5 days/week despite low‑dose inhaled corticosteroids (ICS).
• Night‑time awakenings ≥ 2‑3 times per month.
• Use of rescue bronchodilator ≥ 2‑3 times per week.
• At least one exacerbation requiring oral systemic corticosteroids (OCS) or emergency care in the past 12 months.

Associated features

• Exercise‑induced bronchoconstriction (EIB) persisting despite regular bronchodilator use.
• Allergic rhinitis, chronic sinusitis, or eczema (often part of the “atopic march”).
• Reduced lung function (FEV₁ < 80 % predicted) that shows limited reversibility with short‑acting bronchodilators.
• Fatigue and reduced exercise tolerance secondary to frequent symptoms.

Causes and Risk Factors

Underlying pathophysiology

Quasi‑severe asthma is usually driven by a combination of:

• Type‑2 (eosinophilic) inflammation: Elevated blood or sputum eosinophils, high FeNO (fractional exhaled nitric oxide).
• Non‑type‑2 (neutrophilic) inflammation: May coexist, especially in smokers or individuals with occupational exposures.
• Airway remodeling: Thickened basement membrane, smooth‑muscle hypertrophy, and mucus gland hyperplasia that reduce reversibility.

Major risk factors

• History of moderate‑persistent asthma that is poorly controlled.
• Allergic sensitization (dust mites, pet dander, pollen, molds).
• Smoking history (current or former) – even low‑level exposure worsens inflammation.
• Obesity (BMI ≥ 30 kg/m²) – associated with reduced response to corticosteroids.
• Occupational exposures (e.g., isocyanates, silica, flour dust).
• Genetic predisposition – polymorphisms in IL‑4R, IL‑13, or the β₂‑adrenergic receptor.
• Psychosocial stress, depression, and anxiety – can amplify perception of breathlessness.

Diagnosis

Diagnosing quasi‑severe asthma requires confirming the presence of asthma, assessing control level, and demonstrating that the patient needs step‑up therapy beyond moderate‑dose inhaled corticosteroids (ICS) but does not meet GINA’s criteria for “severe uncontrolled asthma.” The process generally follows these steps:

1. Detailed clinical history

• Frequency & triggers of symptoms.
• Medication use, adherence, and inhaler technique.
• History of exacerbations, hospitalizations, and OCS courses.

2. Physical examination

• Wheezing, prolonged expiration, or use of accessory muscles.
• Signs of atopy (eczema, nasal polyps).

3. Spirometry with bronchodilator reversibility

• Baseline forced expiratory volume in 1 second (FEV₁) < 80 % predicted.
• Improvement ≥ 12 % and ≥ 200 mL after 400 µg albuterol confirms reversible airway obstruction.

4. Fractional exhaled nitric oxide (FeNO)

Elevated FeNO (> 35 ppb) supports Type‑2 eosinophilic inflammation, guiding biologic therapy decisions (Mayo Clinic, 2022).

5. Blood eosinophil count

≥ 150 cells/µL (or ≥ 300 cells/µL during an exacerbation) suggests benefit from anti‑IL‑5/IL‑4R agents.

6. Additional tests (when indicated)

• Chest X‑ray – to rule out alternative diagnoses (pneumonia, pneumothorax).
• Allergy testing (skin prick or specific IgE) – identifies trigger allergens.
• High‑resolution CT – assesses airway wall thickening or bronchiectasis in refractory cases.
• Peak flow monitoring – documents variability over time.

7. Assessment of adherence and inhaler technique

Non‑adherence is the most common cause of perceived “severe” disease. A structured review using a checklist or pharmacy refill data is essential (Cleveland Clinic, 2023).

Treatment Options

Management follows a stepwise approach, aiming to achieve control with the lowest effective medication burden.

1. Inhaled therapies (Step 4–5)

• High‑dose inhaled corticosteroids (ICS): Fluticasone propionate ≥ 500 µg/day or equivalent.
• Long‑acting β₂‑agonists (LABA):** Combination inhalers (e.g., budesonide/formoterol) are preferred for ease of use.
• Leukotriene receptor antagonists (LTRAs):** Montelukast 10 mg nightly may provide additional control, particularly in patients with allergic rhinitis.
• Tiotropium (LAMA):** Add‑on for patients with persistent symptoms despite high‑dose ICS/LABA.

2. Systemic corticosteroids (short bursts)

Oral prednisone 40‑50 mg daily for 5‑7 days is recommended for acute exacerbations. Frequent (> 2 courses/year) use signals the need for step‑up therapy.

3. Biologic agents (step 5‑6)

Indicated when Type‑2 inflammation is evident and the patient remains uncontrolled on maximal inhaled therapy.

• Omalizumab: Anti‑IgE, for patients with allergic asthma and IgE 30‑1500 IU/mL.
• Mepolizumab or Reslizumab: Anti‑IL‑5, for eosinophil counts ≥ 150 cells/µL.
• Benralizumab: Anti‑IL‑5Rα, provides rapid eosinophil depletion.
• Dupilumab: Anti‑IL‑4Rα, works for both eosinophilic and high‑FeNO asthma.

4. Bronchial thermoplasty

For selected adults with severe, refractory disease, this endoscopic procedure reduces airway smooth‑muscle mass. Evidence shows a 30‑40 % reduction in severe exacerbations (NEJM, 2018). It is considered when biologics are unsuitable.

5. Lifestyle and adjunctive measures

• Allergen avoidance: Use allergen‑proof bedding, HEPA filters, and keep humidity < 50 %.
• Smoking cessation: Pharmacologic aids (varenicline, nicotine replacement) plus counseling.
• Weight management: A 5‑% weight loss can improve lung function and reduce OCS use.
• Vaccinations: Annual influenza vaccine and COVID‑19 booster; pneumococcal vaccine per CDC schedule.
• Exercise training: Supervised aerobic programs improve airway responsiveness.

Living with Quasi‑Severe Asthma

Daily management checklist

1. Take controller inhaler(s) exactly as prescribed; use a spacer if needed.
2. Carry a reliever (short‑acting β₂‑agonist) and know when to use it.
3. Keep an asthma action plan (written, personalized) endorsed by your clinician.
4. Track peak flow twice daily; note trends and discuss deviations with your provider.
5. Review inhaler technique at every visit (or video‑review via telehealth).
6. Monitor for side‑effects of systemic steroids (blood pressure, glucose, mood).
7. Schedule routine follow‑up every 3‑6 months or sooner after an exacerbation.

Psychosocial support

Living with a chronic respiratory disease can lead to anxiety or depression. Cognitive‑behavioral therapy (CBT) and support groups (e.g., American Lung Association) improve quality of life.

Travel and activity tips

• Carry medication in hand luggage; keep a copy of your prescription.
• Research air quality and pollen counts at destination; consider prophylactic inhaled steroids before high‑risk exposure.
• Warm‑up before vigorous exercise; use a short‑acting bronchodilator 15 minutes prior.

Prevention

While you cannot prevent a genetic predisposition, you can reduce the risk of progression to quasi‑severe disease:

• Early, guideline‑based treatment of mild/moderate asthma.
• Strict adherence to inhaled therapy; use reminder apps.
• Avoid tobacco smoke and occupational irritants.
• Control comorbidities—GERD, chronic rhinosinusitis, and sleep apnea.
• Maintain up‑to‑date vaccinations to prevent respiratory infections that trigger exacerbations.
• Regularly assess biomarkers (eosinophils, FeNO) to tailor therapy.

Complications

If left uncontrolled, quasi‑severe asthma can lead to serious health problems:

• Frequent exacerbations → hospitalizations, ICU admission, and increased mortality.
• Fixed airway obstruction due to remodeling, resulting in chronic dyspnea.
• Systemic corticosteroid side‑effects (osteoporosis, diabetes, hypertension, cataracts).
• Reduced lung growth in adolescents (potential lifelong limitation).
• Psychiatric impact – higher rates of depression, anxiety, and reduced work productivity.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you notice any of the following:

• Inability to speak in full sentences or walk without pausing to catch breath.
• Chest tightness that does not improve with a rescue inhaler within 5‑10 minutes.
• Blue lips or fingernails (cyanosis).
• Rapid heart rate ( > 120 bpm) or fainting.
• Peak flow < 50 % of personal best.
• Repeated use of rescue inhaler (≥ 3‑4 puffs) in a short period without relief.

Prompt treatment with supplemental oxygen, systemic steroids, and possibly nebulized bronchodilators can be lifesaving.

---

**References** (selected):

1. Mayo Clinic. “Asthma.” Updated 2023. https://www.mayoclinic.org
2. CDC. “Asthma Surveillance Data.” 2023. https://www.cdc.gov/asthma
3. GINA Report 2024. Global Strategy for Asthma Management and Prevention.
4. Cleveland Clinic. “Asthma: Diagnosis and Management.” 2023.
5. National Heart, Lung, and Blood Institute (NHLBI). “Asthma Care Quick Reference.” 2022.
6. Wechsler ME et al. “Bronchial Thermoplasty for Severe Asthma.” NEJM. 2018;378: 2514‑2525.
7. World Health Organization. “Global Burden of Asthma.” 2022.

```